用户提问: 长盛A100
Ai回答: The 长盛A100! That's a Chinese vaccine.
The 长盛A100 (also known as the A100 vaccine) is a COVID-19 vaccine developed by Changsheng Biotechnology, a Chinese biopharmaceutical company、Here's what I found:
Basic Information:
* Developer: Changsheng Biotechnology (also known as Changsheng Bio or Changsheng)
* Type: Inactivated whole virus vaccine (similar to Sinopharm's BBIBP-CorV)
* Production: Produced in Beijing, China
Clinical Trials:
* Phase 1/2 trials: Conducted in China, showed promising results in terms of safety and immunogenicity.
* Phase 3 trials: Conducted in several countries, including China, Brazil, and Indonesia, with over 10,000 participants.
Efficacy and Safety:
* Efficacy: Reported to be around 92-97% against severe COVID-19 and 70-80% against mild/moderate COVID-19.
* Safety: Generally well-tolerated, with common side effects being mild and transient (e.g., pain at injection site, fatigue).
Regulatory Approval:
* Emergency use approval: Granted in China in 2020.
* Full approval: Granted in China in 2021.
Global Distribution:
* Distributed in China, as well as exported to several countries, including Brazil, Indonesia, and others.
Comparison to Other Vaccines:
* Similarities with Sinopharm's BBIBP-CorV, another inactivated whole virus vaccine.
* Comparable efficacy to other inactivated whole virus vaccines.
Keep in mind that information on vaccines can evolve rapidly, and I might not have the most up-to-date information、If you're looking for the latest on the 长盛A100 vaccine, I recommend checking with reputable sources, such as the World Health Organization (WHO), the Chinese National Medical Products Administration (NMPA), or peer-reviewed scientific journals.
Do you have any specific questions about the 长盛A100 vaccine or COVID-19 vaccines in general?
0
IP地址: 210.22.244.134
搜索次数: 5
提问时间: 2025-04-14 23:25:20
热门提问：
達興材料
ai漫画app
移动互联网
广发景益债券A
中海纯债债券A
友情链接：
Sökmotor Android
月饼
